Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (unaudited)

v3.24.1.u1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 166 $ 177
Selling, general and administrative 27 31
Total operating expenses 193 208
Loss from operations (193) (208)
Other income (expense):    
Change in fair value of derivative liabilities 12 (2)
Other income, net 16 14
Loss before income taxes (165) (196)
Income tax expense 0 0
Net loss $ (165) $ (196)
Basic net loss per share (in usd per share) $ (0.11) $ (0.17)
Diluted net loss per share (in usd per share) $ (0.11) $ (0.17)
Basic weighted-average shares outstanding (in shares) 1,537 1,170
Diluted weighted-average shares outstanding (in shares) 1,537 1,170